Recent

% | $
Quotes you view appear here for quick access.

ЕЛН Message Board

  • dar200 dar200 Nov 24, 2004 2:28 PM Flag

    Spinmeister hatchet job

    Such desperation!!! BUT, the news agencies report it.


    NEW YORK (Dow Jones)--Ernesto Bertarelli, chief executive of Serono SA (SRA), said it is misleading to compare its multiple sclerosis drug, Rebif, with fellow MS drug Tysabri.

    Tysabri, which is developed by Biogen Idec (BIIB) and Elan Corp. (ELN), was approved by the Food and Drug Administration late Tuesday.

    In a CNBC interview Wednesday, Bertarelli said there is no data that indicates Tysabri is any more effective that Rebif. He added that he expects Rebif to remain a market leader in the U.S. despite the entrance of Tysabri.

    While a new MS alternative is great, Bertarelli said, Rebif has had a long history of proven safety and efficacy; however, no long-term studies of Tysabri have been done, he said.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ELN
0.0000(0.00%)